NEW YORK, Jan. 9 (GenomeWeb News) - Merck has extended its global enterprise agreement with GeneGo for its data-mining suite for two more years, GeneGo said today.
Merck researchers will continue to use GeneGo's MetaCore data-mining suite in research and development activities.
They will also retain direct access to MetaBase, a database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature.
MetaCore and MetaBase have been integrated with Merck's discovery informatics platform and are used across multiple therapeutic areas.
Financial details were not disclosed.